Compare PCVX & NOVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | NOVT |
|---|---|---|
| Founded | 2013 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.7B |
| IPO Year | 2020 | 1999 |
| Metric | PCVX | NOVT |
|---|---|---|
| Price | $60.78 | $144.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $88.25 | ★ $144.00 |
| AVG Volume (30 Days) | ★ 1.6M | 533.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.51 |
| Revenue | N/A | ★ $521,290,000.00 |
| Revenue This Year | N/A | $8.61 |
| Revenue Next Year | N/A | $6.57 |
| P/E Ratio | ★ N/A | $323.29 |
| Revenue Growth | N/A | ★ 35.49 |
| 52 Week Low | $29.10 | $98.27 |
| 52 Week High | $65.00 | $171.85 |
| Indicator | PCVX | NOVT |
|---|---|---|
| Relative Strength Index (RSI) | 67.92 | 40.07 |
| Support Level | $42.30 | $131.26 |
| Resistance Level | $64.16 | $149.42 |
| Average True Range (ATR) | 2.56 | 7.17 |
| MACD | 0.95 | -0.89 |
| Stochastic Oscillator | 94.88 | 2.91 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.